Jeffrey K. Smith
Direktor/Vorstandsmitglied bei Electrophysiology Research Foundation
Ursprung des Netzwerks ersten Grades von Jeffrey K. Smith
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Electrophysiology Research Foundation
 Electrophysiology Research Foundation Miscellaneous Commercial ServicesCommercial Services Electrophysiology Research Foundation operates as a charitable non-profit organization devoted solely to research and education in cardiac electrophysiology. It engages in the conducting research studies in the field of cardiac pharmacology, cardiac lectrophysiology, arrhythmia ablation, implantable pacemakers, and implantable cardioverter-defibrillators. The firm conducts and coordinates multicenter clinical trials, and basic research in cardiac electrophysiology and cardiac pacing. The company was founded by Sanjeev Saksena on August 2, 1982 and is headquartered in Warren, NJ.
4
| Non-Profit Organization | Miscellaneous Commercial Services | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Jeffrey K. Smith
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BIOCLINICA INC | Medical/Nursing Services | Director/Board Member | |
| ARROWHEAD PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
| ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| NORDION INC | Pharmaceuticals: Major | Director/Board Member | |
Neusentis, Inc.
 Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member | |
| SEMBIOSYS GENETICS I | Biotechnology | Director/Board Member | |
| MILESTONE PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
| VIA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder | |
BioMedical Systems Corp.
 BioMedical Systems Corp. Medical/Nursing ServicesHealth Services BioMedical Systems Corp. provides centralized diagnostic services to pharmaceutical and medical industries. It offers cardiac modalities, including digital 12-lead electrocardiogram (ECG), TQT/intensive studies, Holter monitoring, ambulatory blood pressure monitoring, and ECG stress testing. The firm also centralizes pulmonary function testing in pharmaceutical and medical device clinical trials for the modalities, including spirometry, peak flow with eDiary, challenge testing, pulse oximetry, nitric oxide, and DLco/lung volumes. The company was founded by W. Raymond Barrett in 1975 and is headquartered in St. Louis, MO. | Medical/Nursing Services | Director/Board Member | |
D&R Greenway Land Trust, Inc.
 D&R Greenway Land Trust, Inc. Miscellaneous Commercial ServicesCommercial Services D&R Greenway Land Trust is a non-profit organization which works to preserve and protect a permanent network of natural lands and open spaces in central New Jersey. The company was founded by Jim Amon, Rosemary Blair, Dennis Davidson, Sam Hamill, and Bob Johnston in 1989 and is headquartered in Princeton, NJ. | Miscellaneous Commercial Services | Director/Board Member | |
| CR Strategies LLC | Chief Executive Officer | ||
Abcentra, Inc.
 Abcentra, Inc. Miscellaneous Commercial ServicesCommercial Services Abcentra, Inc. is an American clinical-stage biopharmaceutical company that specializes in developing novel antibody therapies for inflammatory diseases, with a particular focus on cardiovascular disease. The private company's patented technology allows for the targeting of oxidized lipoproteins and associated inflammatory responses. Abcentra's pipeline focuses on patient populations with high-risk of cardiometabolic complications that are exacerbated by chronic inflammation, including patients with inflammatory diseases and patients with residual inflammation. The company's lead compound, orticumab, is a novel monoclonal antibody that blocks inflammation from oxidized low-density lipoprotein and is slated to begin a phase 2 study later this year. Kevin B. Bacon has been the CEO of the company since 2020. | Miscellaneous Commercial Services | Chief Executive Officer | |
| Albert Einstein College of Medicine, Inc. | College/University | Doctorate Degree | |
| DIADEXUS, INC. | Biotechnology | Director/Board Member | |
| Harvard T.H. Chan School of Public Health | College/University | Graduate Degree | |
| Cardio Vax LLC | Chief Executive Officer | ||
| TONIX PHARMACEUTICALS HOLDING CORP. | Pharmaceuticals: Major | Director/Board Member | |
| UNC School of Law | College/University | Undergraduate Degree | |
Epigen Pharmaceuticals, Inc.
 Epigen Pharmaceuticals, Inc. BiotechnologyHealth Technology Epigen Pharmaceuticals, Inc. develops cardiac reperfusion therapies. The private company is based in Princeton. | Biotechnology | Chief Executive Officer |
Statistik
International
| Vereinigte Staaten | 20 |
| Kanada | 5 |
Sektoral
| Health Technology | 14 |
| Consumer Services | 4 |
| Health Services | 3 |
| Commercial Services | 3 |
| Finance | 2 |
Operativ
| Director/Board Member | 18 |
| Independent Dir/Board Member | 6 |
| Chief Executive Officer | 6 |
| Chief Tech/Sci/R&D Officer | 3 |
| Founder | 3 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Adeoye Olukotun | 24 |
| Sanjeev Saksena | 1 |
| Donald J. Saltzman | 1 |
| Mary Powers | 1 |
- Börse
- Insiders
- Jeffrey K. Smith
- Unternehmensverbindungen
